Chemotherapy-induced peripheral neuropathy: An increasing concern for oncologists Maurie Markman Editor’s Commentary Pages: 159 - 160
First-line therapy for advanced colorectal cancer Aimery de GramontChristophe TournigandThierry André OriginalPaper Pages: 167 - 172
Second-line therapy for advanced colorectal carcinoma Naureen StarlingDavid Cunningham OriginalPaper Pages: 173 - 180
Chemotherapy for advanced pancreatic cancer: Past, present, and future Gregory FribergHedy Lee Kindler OriginalPaper Pages: 186 - 195
Chemoradiotherapy for gastrointestinal cancers Tyvin A. RichChristopher CraneJerome Landry OriginalPaper Pages: 196 - 202
Docetaxel-based chemotherapy trials in androgen-independent prostate cancer: First demonstration of a survival benefit Daniel P. Petrylak Clinical Trials Report Pages: 205 - 206
Adjuvant chemotherapy for transitional cell carcinoma of the bladder: Paradigms for the design of clinical trials Michelle BoyarDaniel P. Petrylak OriginalPaper Pages: 207 - 214
Angiogenesis and prostate cancer: Important laboratory and clinical findings Michael C. CoxMatthew PermenterWilliam D. Figg OriginalPaper Pages: 215 - 219
Chemotherapy for advanced prostate cancer: Results of new clinical trials and future studies Andrew J. ArmstrongMichael A. Carducci OriginalPaper Pages: 220 - 227
Secondary hormonal manipulations in prostate cancer Charles J. RyanEric J. Small OriginalPaper Pages: 228 - 233
